Hughes WT, Armstrong D, Bodey GP, etal (March 2002). “2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer”. Clin. Infect. Dis.34 (6): 730–51. doi:10.1086/339215. ISSN1058-4838. PMID11850858.
Klastersky J, Paesmans M, Rubenstein EB, etal (16 August 2000). “The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.”. J Clin Oncol18 (16): 3038–51. doi:10.1200/JCO.2000.18.16.3038. ISSN0732-183X. PMID10944139.
de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (July 2008). “Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients”. Supportive Care in Cancer16 (7): 841–6. doi:10.1007/s00520-007-0347-3. ISSN0941-4355. PMID17960431.
Paul M, Yahav D, Fraser A, Leibovici L (February 2006). “Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials”. J. Antimicrob. Chemother.57 (2): 176–89. doi:10.1093/jac/dki448. ISSN0305-7453. PMID16344285.
Paul, Mical; Yahav, Dafna; Bivas, Assaf; Fraser, Abigail; Leibovici, Leonard (2010-11-10). “Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams”. Cochrane Database of Systematic Reviews (11): CD005197. doi:10.1002/14651858.cd005197.pub3. ISSN1465-1858. PMID21069685.
Flowers, Christopher R.; Seidenfeld, Jerome; Bow, Eric J.; Karten, Clare; Gleason, Charise; Hawley, Douglas K.; Kuderer, Nicole M.; Langston, Amelia A. et al. (2013-02-20). “Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline”. Journal of Clinical Oncology31 (6): 794–810. doi:10.1200/JCO.2012.45.8661. ISSN1527-7755. PMID23319691.
Hughes WT, Armstrong D, Bodey GP, etal (March 2002). “2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer”. Clin. Infect. Dis.34 (6): 730–51. doi:10.1086/339215. ISSN1058-4838. PMID11850858.
Klastersky J, Paesmans M, Rubenstein EB, etal (16 August 2000). “The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.”. J Clin Oncol18 (16): 3038–51. doi:10.1200/JCO.2000.18.16.3038. ISSN0732-183X. PMID10944139.
de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (July 2008). “Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients”. Supportive Care in Cancer16 (7): 841–6. doi:10.1007/s00520-007-0347-3. ISSN0941-4355. PMID17960431.
Paul M, Yahav D, Fraser A, Leibovici L (February 2006). “Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials”. J. Antimicrob. Chemother.57 (2): 176–89. doi:10.1093/jac/dki448. ISSN0305-7453. PMID16344285.
Paul, Mical; Yahav, Dafna; Bivas, Assaf; Fraser, Abigail; Leibovici, Leonard (2010-11-10). “Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams”. Cochrane Database of Systematic Reviews (11): CD005197. doi:10.1002/14651858.cd005197.pub3. ISSN1465-1858. PMID21069685.
Flowers, Christopher R.; Seidenfeld, Jerome; Bow, Eric J.; Karten, Clare; Gleason, Charise; Hawley, Douglas K.; Kuderer, Nicole M.; Langston, Amelia A. et al. (2013-02-20). “Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline”. Journal of Clinical Oncology31 (6): 794–810. doi:10.1200/JCO.2012.45.8661. ISSN1527-7755. PMID23319691.
Hughes WT, Armstrong D, Bodey GP, etal (March 2002). “2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer”. Clin. Infect. Dis.34 (6): 730–51. doi:10.1086/339215. ISSN1058-4838. PMID11850858.
Klastersky J, Paesmans M, Rubenstein EB, etal (16 August 2000). “The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.”. J Clin Oncol18 (16): 3038–51. doi:10.1200/JCO.2000.18.16.3038. ISSN0732-183X. PMID10944139.
de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (July 2008). “Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients”. Supportive Care in Cancer16 (7): 841–6. doi:10.1007/s00520-007-0347-3. ISSN0941-4355. PMID17960431.
Paul M, Yahav D, Fraser A, Leibovici L (February 2006). “Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials”. J. Antimicrob. Chemother.57 (2): 176–89. doi:10.1093/jac/dki448. ISSN0305-7453. PMID16344285.
Paul, Mical; Yahav, Dafna; Bivas, Assaf; Fraser, Abigail; Leibovici, Leonard (2010-11-10). “Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams”. Cochrane Database of Systematic Reviews (11): CD005197. doi:10.1002/14651858.cd005197.pub3. ISSN1465-1858. PMID21069685.
Flowers, Christopher R.; Seidenfeld, Jerome; Bow, Eric J.; Karten, Clare; Gleason, Charise; Hawley, Douglas K.; Kuderer, Nicole M.; Langston, Amelia A. et al. (2013-02-20). “Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline”. Journal of Clinical Oncology31 (6): 794–810. doi:10.1200/JCO.2012.45.8661. ISSN1527-7755. PMID23319691.